137 related articles for article (PubMed ID: 23947184)
1. [Companion diagnostics and reimbursement system].
Tazawa Y
Rinsho Byori; 2013 May; 61(5):435-42. PubMed ID: 23947184
[TBL] [Abstract][Full Text] [Related]
2. [The current issues on development and clinical use of companion diagnostics and prospects of personalized medicine for the future].
Tazawa Y
Yakugaku Zasshi; 2014; 134(4):491-8. PubMed ID: 24694808
[TBL] [Abstract][Full Text] [Related]
3. [Current issues regarding companion diagnostics and future prospects].
Tazawa Y
Rinsho Byori; 2014 Apr; 62(4):381-9. PubMed ID: 25022068
[TBL] [Abstract][Full Text] [Related]
4. Payers and the assessment of clinical utility for companion diagnostics.
Quinn B
Clin Pharmacol Ther; 2010 Dec; 88(6):751-4. PubMed ID: 21081944
[TBL] [Abstract][Full Text] [Related]
5. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
6. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
7. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
8. [Companion Diagnostics for Solid Tumors].
Watanabe A
Rinsho Byori; 2015 Nov; 63(11):1310-5. PubMed ID: 26995877
[TBL] [Abstract][Full Text] [Related]
9. [Current situation and challenges in companion diagnostics development].
Nishida M
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2529-34. PubMed ID: 25596043
[TBL] [Abstract][Full Text] [Related]
10. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
Frueh FW
Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
[TBL] [Abstract][Full Text] [Related]
11. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
14. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
15. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
16. The Health Technology Assessment of companion diagnostics: experience of NICE.
Byron SK; Crabb N; George E; Marlow M; Newland A
Clin Cancer Res; 2014 Mar; 20(6):1469-76. PubMed ID: 24634470
[TBL] [Abstract][Full Text] [Related]
17. Towards a balanced value business model for personalized medicine: an outlook.
Koelsch C; Przewrocka J; Keeling P
Pharmacogenomics; 2013 Jan; 14(1):89-102. PubMed ID: 23252951
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacoeconomics--survey and status].
Pedersen KM
Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
[TBL] [Abstract][Full Text] [Related]
19. Technology assessment for new oncology drugs.
Jönsson B
Clin Cancer Res; 2013 Jan; 19(1):6-11. PubMed ID: 23288370
[TBL] [Abstract][Full Text] [Related]
20. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]